1. Home
  2. BDRX
  3. BDRX News

Latest Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) News on July 26, 2024

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
BDRX

GlobeNewswire

3 days ago

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
BDRX

GlobeNewswire

7 days ago

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada
BDRX

GlobeNewswire

10 days ago

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data
BDRX

ACCESSWIRE

15 days ago

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
BDRX

GlobeNewswire

24 days ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)
BDRX

GlobeNewswire

a month ago

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting
BDRX

GlobeNewswire

a month ago

Results of Annual General Meeting

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
BDRX

GlobeNewswire

2 months ago

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024
BDRX

CNW Group

2 months ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
BDRX

ACCESSWIRE

2 months ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
BDRX

Business Insider

2 months ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
BDRX

GlobeNewswire

2 months ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
BDRX

Motley Fool

2 months ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro
BDRX

CNW Group

2 months ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly
BDRX

AFP

2 months ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires
BDRX

Business Insider

2 months ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
BDRX

ACCESSWIRE

2 months ago

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

BDRX

GlobeNewswire

2 months ago

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
BDRX

GlobeNewswire

2 months ago

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Posting of Annual Report & Notice of AGM - Total Voting Rights
BDRX

GlobeNewswire

2 months ago

Posting of Annual Report & Notice of AGM - Total Voting Rights

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
BDRX

ACCESSWIRE

3 months ago

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
BDRX

GlobeNewswire

3 months ago

Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
BDRX

GlobeNewswire

3 months ago

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

Preliminary Results for the Year Ended 31 December 2023
BDRX

GlobeNewswire

3 months ago

Preliminary Results for the Year Ended 31 December 2023

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
BDRX

ACCESSWIRE

4 months ago

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
BDRX

ACCESSWIRE

5 months ago

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
BDRX

GlobeNewswire

5 months ago

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
BDRX

GlobeNewswire

6 months ago

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
BDRX

GlobeNewswire

6 months ago

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
BDRX

GlobeNewswire

6 months ago

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
BDRX

PR Newswire

6 months ago

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

LENSAR Decline Means Insider Profits Down To US$42k
BDRX

Simply Wall St.

6 months ago

LENSAR Decline Means Insider Profits Down To US$42k

BDRX

PR Newswire

6 months ago

/DISREGARD RELEASE: Visionary Education Technology Holdings Group Inc./

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
BDRX

GlobeNewswire

6 months ago

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa
BDRX

Business Wire

6 months ago

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

BDRX

ACCESSWIRE

6 months ago

Vision Marine Technologies Inc. Announces Close of $3.0 Million Private Placement of Convertible Preferred Shares and Warrants with Investissement Québec

Visionary Education Group Established a MOU with Algoma University
BDRX

PR Newswire

6 months ago

Visionary Education Group Established a MOU with Algoma University

Vision Marine Technologies Inc. (VMAR) Reports Q1 Loss, Misses Revenue Estimates
BDRX

Zacks

6 months ago

Vision Marine Technologies Inc. (VMAR) Reports Q1 Loss, Misses Revenue Estimates

Hepion Pharmaceuticals to Present at NASH-TAG 2024
BDRX

GlobeNewswire

7 months ago

Hepion Pharmaceuticals to Present at NASH-TAG 2024

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
BDRX

GlobeNewswire

7 months ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Edgio Promotes Todd Hinders to Chief Executive Officer
BDRX

Business Wire

7 months ago

Edgio Promotes Todd Hinders to Chief Executive Officer

Biodexa Appoints Ann Merchant to the Board of Directors
BDRX

GlobeNewswire

7 months ago

Biodexa Appoints Ann Merchant to the Board of Directors

12 Most Profitable Pot Stocks Now
BDRX

Insider Monkey

7 months ago

12 Most Profitable Pot Stocks Now

La Rosa Acquires Fifth Real Estate Brokerage Franchisee with Revenue of $3.6 Million and Positive Net Income in 2022
BDRX

GlobeNewswire

7 months ago

La Rosa Acquires Fifth Real Estate Brokerage Franchisee with Revenue of $3.6 Million and Positive Net Income in 2022

11 Popular Penny Stocks on Robinhood
BDRX

Insider Monkey

7 months ago

11 Popular Penny Stocks on Robinhood

BDRX

GlobeNewswire

7 months ago

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
BDRX

GlobeNewswire

7 months ago

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

CORRECTING and REPLACING Edgio Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
BDRX

Business Wire

7 months ago

CORRECTING and REPLACING Edgio Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Safeguard Scientifics’ Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share
BDRX

GlobeNewswire

8 months ago

Safeguard Scientifics’ Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share

BDRX

GlobeNewswire

8 months ago

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes

SteraMist Welcomes Sterile Grow as U.S. Distributor for Food Safety and Cannabis
BDRX

GlobeNewswire

8 months ago

SteraMist Welcomes Sterile Grow as U.S. Distributor for Food Safety and Cannabis

BDRX

Associated Press Finance

8 months ago

Ituran: Q3 Earnings Snapshot

ITURAN PRESENTS THIRD QUARTER 2023 RESULTS
BDRX

PR Newswire

8 months ago

ITURAN PRESENTS THIRD QUARTER 2023 RESULTS

BDRX

PR Newswire

8 months ago

Jianpu Technology Inc. Reports Third Quarter 2023 Unaudited Financial Results

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon
BDRX

Simply Wall St.

8 months ago

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

Insider Spends US$59k Buying More Shares In Crown Crafts
BDRX

Simply Wall St.

8 months ago

Insider Spends US$59k Buying More Shares In Crown Crafts

BDRX

InvestorPlace

8 months ago

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
BDRX

GlobeNewswire

8 months ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

BDRX

PR Newswire

8 months ago

Jianpu Technology Inc. to Report Third Quarter 2023 Financial Results on Friday, November 24, 2023

When Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?
BDRX

Simply Wall St.

8 months ago

When Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?

SAI.TECH Global Corporation Reports Unaudited Financial Results for the Six Months Ended June 30, 2023
BDRX

GlobeNewswire

8 months ago

SAI.TECH Global Corporation Reports Unaudited Financial Results for the Six Months Ended June 30, 2023

Orion Energy Systems, Inc. (NASDAQ:OESX) Q2 2024 Earnings Call Transcript
BDRX

Insider Monkey

9 months ago

Orion Energy Systems, Inc. (NASDAQ:OESX) Q2 2024 Earnings Call Transcript

Share on Social Networks: